Table 1:

Baseline patient and tumor characteristics

Evaluable patients, n	170
Median age (range), years	67 (45–87)
Race, n (%)
White	140 (82)
Black/African American	17 (10)
Other	13 (8)
Median ECOG performance status (range)	1 (0–1)
Prior treatments
Median prior hormonal treatment lines (range)	2 (1–5)
Prior anti-androgens, n (%)	105 (62)
Prior chemotherapy, n (%)	34 (20)
Median PSA at baseline (range), ng/mL	20.7 (0.6 – 1655.4)
Gleason score at diagnosis, n (%)
≤7	43 (25)
≥ 8	101 (72)
Not evaluable	26 (15)
≥20 Bone Metastases, n (%)	46 (27)
Visceral Metastases, n (%)	23 (14)
Bone marrow infiltration, n (%)
Baseline	48 (28)
Evaluable for biomarker analysis at baseline	46 (27)
Any time point	53 (31)

ECOG= Eastern Cooperative Oncology Group; PSA= prostate specific antigen